Aprea Therapeutics, Inc.
APRE
$0.90
-$0.03-3.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.60M | -13.04M | -13.85M | -14.08M | -12.96M |
| Total Depreciation and Amortization | 21.60K | 21.60K | 21.60K | 21.50K | 22.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 612.50K | 542.50K | 607.70K | 575.80K | 435.10K |
| Change in Net Operating Assets | -929.20K | -969.70K | 479.50K | 231.80K | -1.06M |
| Cash from Operations | -12.89M | -13.44M | -12.74M | -13.25M | -13.56M |
| Capital Expenditure | -- | 0.00 | 0.00 | -7.50K | -15.50K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | 0.00 | -7.50K | -15.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.05M | 975.20K | 599.80K | 200.00K | 16.14M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -407.40K | -42.10K | -25.90K | -32.10K | -1.32M |
| Cash from Financing | 4.64M | 933.00K | 573.90K | 167.90K | 14.82M |
| Foreign Exchange rate Adjustments | 4.70K | -21.20K | 4.10K | -3.30K | -7.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -8.25M | -12.53M | -12.16M | -13.09M | 1.24M |